ABBV - Assessing AbbVie's Performance Against Competitors In Biotechnology Industry | Benzinga
In the fast-paced and highly competitive business world of today, conducting thorough company analysis is essential for investors and industry observers. In this article, we will conduct an extensive industry comparison, evaluating AbbVie (NYSE:ABBV) in relation to its major competitors in the Biotechnology industry. Through a detailed examination of key financial metrics, market standing, and growth prospects, our objective is to provide valuable insights and illuminate company's performance in the industry.
AbbVie Background
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
| Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
|---|---|---|---|---|---|---|---|
| AbbVie Inc | |||||||
| 65.64 | |||||||
| 30.51 | |||||||
| 5.83 | |||||||
| 6.94% | |||||||
| $3.85 | |||||||
| $8.6 | |||||||
| -5.42% | |||||||
| Amgen Inc | |||||||
| 22.48 | |||||||
| 24.15 | |||||||
| 5.36 | |||||||
| 11.05% | |||||||
| $3.05 | |||||||
| $5.08 | |||||||
| 19.84% | |||||||
| Vertex Pharmaceuticals Inc | |||||||
| 29.95 | |||||||
| 6.11 | |||||||
| 10.98 | |||||||
| 5.68% | |||||||
| $1.22 | |||||||
| $2.15 | |||||||
| 9.34% | |||||||
| Regeneron Pharmaceuticals Inc | |||||||
| 27.64 | |||||||
| 4.06 | |||||||
| 8.33 | |||||||
| 4.56% | |||||||
| $1.28 | |||||||
| $2.92 | |||||||
| 0.58% | |||||||
| Gilead Sciences Inc | |||||||
| 16.13 | |||||||
| 3.96 | |||||||
| 3.37 | |||||||
| 6.33% | |||||||
| $2.59 | |||||||
| $5.02 | |||||||
| -3.72% | |||||||
| Biogen Inc | |||||||
| 27.19 | |||||||
| 2.13 | |||||||
| 3.21 | |||||||
| 1.71% | |||||||
| $0.5 | |||||||
| $1.77 | |||||||
| -6.2% | |||||||
| BioNTech SE | |||||||
| 22.36 | |||||||
| 1.01 | |||||||
| 5.44 | |||||||
| 2.28% | |||||||
| $0.46 | |||||||
| $1.3 | |||||||
| -65.43% | |||||||
| Genmab A/S | |||||||
| 31.18 | |||||||
| 4.25 | |||||||
| 8.24 | |||||||
| 2.04% | |||||||
| $0.93 | |||||||
| $4.55 | |||||||
| -8.94% | |||||||
| Biomarin Pharmaceutical Inc | |||||||
| 99.45 | |||||||
| 3.30 | |||||||
| 6.85 | |||||||
| 0.41% | |||||||
| $0.05 | |||||||
| $0.51 | |||||||
| 20.22% | |||||||
| Neurocrine Biosciences Inc | |||||||
| 56.78 | |||||||
| 6.25 | |||||||
| 7.51 | |||||||
| 6.98% | |||||||
| $0.2 | |||||||
| $0.51 | |||||||
| 25.05% | |||||||
| Incyte Corp | |||||||
| 21.69 | |||||||
| 2.49 | |||||||
| 3.51 | |||||||
| 3.97% | |||||||
| $0.29 | |||||||
| $0.94 | |||||||
| 9.35% | |||||||
| United Therapeutics Corp | |||||||
| 12.33 | |||||||
| 1.92 | |||||||
| 5.22 | |||||||
| 3.71% | |||||||
| $0.32 | |||||||
| $0.54 | |||||||
| 25.07% | |||||||
| Roivant Sciences Ltd | |||||||
| 1.89 | |||||||
| 1.32 | |||||||
| 64.89 | |||||||
| 144.81% | |||||||
| $5.11 | |||||||
| $0.03 | |||||||
| 117.8% | |||||||
| Exelixis Inc | |||||||
| 36.46 | |||||||
| 3.17 | |||||||
| 4.16 | |||||||
| 3.71% | |||||||
| $0.09 | |||||||
| $0.46 | |||||||
| 13.15% | |||||||
| Average | |||||||
| 31.19 | |||||||
| 4.93 | |||||||
| 10.54 | |||||||
| 15.17% | |||||||
| $1.24 | |||||||
| $1.98 | |||||||
| 12.01% |